The use of cytokines, fusion proteins and antibodies to treat cutaneous T-cell lymphoma

Alain H Rook; Karen S McGinnis; Stephen K Richardson; Jeanne B Budgin; Maria Wysocka; Bernice M Benoit; Jacqueline M J Hopkins; Carmela C Vittorio

doi:10.1111/j.1396-0296.2003.01645.x

The use of cytokines, fusion proteins and antibodies to treat cutaneous T-cell lymphoma

Dermatol Ther. 2003;16(4):331-6. doi: 10.1111/j.1396-0296.2003.01645.x.

Authors

Alain H Rook¹, Karen S McGinnis, Stephen K Richardson, Jeanne B Budgin, Maria Wysocka, Bernice M Benoit, Jacqueline M J Hopkins, Carmela C Vittorio

Affiliation

¹ Department of Dermatology, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA. arook@mail.med.upenn.edu

PMID: 14686976
DOI: 10.1111/j.1396-0296.2003.01645.x

Abstract

It has long been known that certain immune augmenting therapeutics, particularly interferon alpha, can exert profound salutary effects on the clinical progress of patients with cutaneous T-cell lymphoma. Emerging evidence that the host immune response may play an important role in the control of this disorder has led to the clinical application of other cytokines including interleukin-12 and interferon gamma. In this review, the authors will summarize current knowledge regarding the use of cytokines, fusion proteins and antibodies for the treatment of cutaneous T-cell lymphoma.

Publication types

Comparative Study
Review

MeSH terms

Antibodies, Monoclonal / therapeutic use*
Clinical Trials as Topic
Cytokines / therapeutic use*
Drug Therapy, Combination
Female
Humans
Immunotherapy / methods
Interferons / therapeutic use*
Interleukins / therapeutic use*
Lymphoma, T-Cell, Cutaneous / diagnosis
Lymphoma, T-Cell, Cutaneous / mortality
Lymphoma, T-Cell, Cutaneous / therapy*
Male
Neoplasm Staging
Prognosis
Risk Assessment
Skin Neoplasms / diagnosis
Skin Neoplasms / mortality
Skin Neoplasms / therapy*
Survival Analysis
Treatment Outcome

Substances

Antibodies, Monoclonal
Cytokines
Interleukins
Interferons